Optimization and characterization of tannic acid loaded niosomes for enhanced antibacterial and anti-biofilm activities

Heidari, Fatemeh; Akbarzadeh, Iman; Nourouzian, D; Mirzaie, Amir; Bakhshandeh, Haleh

doi:10.1016/j.apt.2020.11.008

Cited by 50 publications

(32 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…"Thin-layer hydration method" prepared the drug-loaded Niosomes containing cholesterol, span60 and tween60, reported in our previous work with minor modifications [27,30]. Briefly, surfactants and cholesterol, were dissolved in 10 mL chloroform as organic solvent.…”

Section: Melittin Loaded Niosomes Preparationmentioning

confidence: 99%

“…Nanoparticles have been designed for optimizing size and characteristics to magnify the biodistribution of cancer drugs in the bloodstream. They can transfer their loaded active drug to cancer cells by selectively using tumors' speci c stimuli [27,28]. Drug resistance is another obstacle that hinders the e cacy of molecularly targeted and precise chemotherapeutic operators and can reduce nanoparticle applications.…”

Section: Introductionmentioning

confidence: 99%

“…Drug delivery systems are characterized as formulations aiming to convey a drug to the desired area of action through the body [29]. Niosomes are special drug carriers developed by the self-association of cholesterol and nonionic surfactants in an aqueous phase [27,29]. They are an alternative to phospholipid vesicles to encapsulate hydrophobic and hydrophilic drugs providing su cient encapsulation capability, biocompatibility, biodegradation, low preparation cost, and ample stability [28,29].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Delivery of Melittin Loaded Niosomes for Breast Cancer Treatment: an in-vitro and in-vivo Evaluation of Anti-cancer Effect

Moghaddam

Akbarzadeh

Marzbankia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundMelittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, Melittin and Melittin loaded niosome had been optimized and assessed the anticancer effect an In-Vitro on 4T1 and SKBR3 breast cell lines and In-Vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the Niosomes; different niosomal formulations of Melittin were prepared and characterized in terms of morphology, size, Polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with Melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of Melittin, and Melittin loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the genes expression. 35 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done.Results: This study showed Melittin loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The Melittin loaded niosome affect the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2, MMP2, and MMP9 genes while they up-regulate the expression of Bax, Caspase3 and Caspase9 genes. Also enhanced the apoptosis rate and inhibitored cell migration, invasion in both cell lines compared to the Melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in Melittin loaded niosome. Renal and hepatic biomarker activity did not show a significant difference in Melittin loaded niosome and Melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups.Conclusions: Our study successfully declares that Melittin loaded niosome had more anti-cancer effects than free Melittin. This project has demonstrated that Niosomes are suitable vesicle carriers for Melittin, compare to free form.

show abstract

Section: Melittin Loaded Niosomes Preparationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Delivery of Melittin Loaded Niosomes for Breast Cancer Treatment: an in-vitro and in-vivo Evaluation of Anti-cancer Effect

Moghaddam

Akbarzadeh

Marzbankia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The initial phase involves the almost accelerated release of letrozole and then followed by a more passive release phase. The rapid initial release can be attributed to the release of loosely attached drug molecules on the surface of the vesicles and the slower phase is fundamentally related to the diffusion of letrozole through the bilayers [37][38][39] .…”

Section: Discussionmentioning

confidence: 99%

An Optimized and Well-Characterized Niosome-Based Nanocarrier for Letrozole: A Brand- New Hybrid Therapy for Breast Cancer

Ahmadi

Akbarzadeh

Chiani

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

This study aimed to improve the anticancer activity of letrozole through a niosomal formulation. Optimized niosomal formulation of letrozole was achieved by response surface methodology (RSM). The niosomes were well-characterized by several methods. The anticancer activity and its mechanism were studied in MCF-7 and MDA-MB-231 breast cancer cells. The release of the drug from the niosomes was according to the Kors Meyer-Peppa kinetic model. The niosomes were stable with high encapsulation efficiency. Significant higher anticancer activity and more induction of apoptosis were obtained for niosomal letrozole. Results indicated that niosomes could be a promising drug carrier for delivery of letrozole to breast cancer cells.

show abstract

“…The use of drug delivery systems is essential to improve the timing, location, and speed of drug release, as well as to prevent drug fluctuations in the circulatory system that lead to lower efficacy and greater side effects ( Vikas et al, 2011 ; Shirzad et al, 2019 ; Shad et al, 2020 ). Progress in nanotechnology led to the development of nano-carriers that are able to carry drugs to the target site ( Ladavière and Gref, 2015 ; Heidari et al, 2020 ). Nano-carriers have benefits such as increased drug solubility, increased drug half-life, controlled release, targeted delivery, reduced side effects, the ability to transfer multiple drugs simultaneously, protecting the drug from degradation, and protecting the patient from immune responses to the drug ( Zhang et al, 2008 ; Banyal et al, 2013 ; Ghafelehbashi et al, 2019 ; Akbarzadeh et al, 2021a ).…”

Section: Introductionmentioning

confidence: 99%

Streptomycin Sulfate–Loaded Niosomes Enables Increased Antimicrobial and Anti-Biofilm Activities

Mansouri

Khayam

Jamshidifar

et al. 2021

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

One of the antibiotics used to treat infections is streptomycin sulfate that inhibits both Gram-negative and -positive bacteria. Nanoparticles are suitable carriers for the direct delivery and release of drug agents to infected locations. Niosomes are one of the new drug delivery systems that have received much attention today due to their excellent biofilm penetration property and controlled release. In this study, niosomes containing streptomycin sulfate were prepared by using the thin layer hydration method and optimized based on the size, polydispersity index (PDI), and encapsulation efficiency (EE%) characteristics. It was found that the Span 60-to-Tween 60 ratio of 1.5 and the surfactant-to-cholesterol ratio of 1.02 led to an optimum formulation with a minimum of size, low PDI, and maximum of EE of 97.8 nm, 0.27, and 86.7%, respectively. The drug release investigation showed that 50.0 ± 1.2% of streptomycin sulfate was released from the niosome in 24 h and reached 66.4 ± 1.3% by the end of 72 h. Two-month stability studies at 25° and 4°C showed more acceptable stability of samples kept at 4°C. Consequently, antimicrobial and anti-biofilm activities of streptomycin sulfate–loaded niosomes against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were found significantly higher than those of free drug, and the minimum inhibitory concentration values decreased 4- to 8-fold. Furthermore, niosome-encapsulated streptomycin up to 1,500 μg/ml exhibited negligible cytotoxicity against the human foreskin fibroblasts cell line, whereas the free drug exhibited slight cytotoxicity at this concentration. Desired physical characteristics and low toxicity of niosomal nano-carriers containing streptomycin sulfate made them a demanded candidate for the treatment of current bacterial infections and biofilms.

show abstract

Optimization and characterization of tannic acid loaded niosomes for enhanced antibacterial and anti-biofilm activities

Cited by 50 publications

References 56 publications

Delivery of Melittin Loaded Niosomes for Breast Cancer Treatment: an in-vitro and in-vivo Evaluation of Anti-cancer Effect

Delivery of Melittin Loaded Niosomes for Breast Cancer Treatment: an in-vitro and in-vivo Evaluation of Anti-cancer Effect

An Optimized and Well-Characterized Niosome-Based Nanocarrier for Letrozole: A Brand- New Hybrid Therapy for Breast Cancer

Streptomycin Sulfate–Loaded Niosomes Enables Increased Antimicrobial and Anti-Biofilm Activities

Contact Info

Product

Resources

About